-
Mashup Score: 3
TPS8075 Background: Standard of care for SMM includes active monitoring until progression to multiple myeloma (MM); however, recent evidence suggests pts with high-risk features may benefit from early treatment. DARA is a human IgGκ monoclonal antibody targeting CD38 that is approved as monotherapy for relapsed/refractory MM (RRMM) or in combination with standard of care for RRMM or newly diagnosed MM. Results from the phase 3 COLUMBA study showed that DARA SC demonstrated similar efficacy to intravenous (IV) DARA but with a lower rate of infusion-related reactions and shorter administration time. Based on the promising single-agent activity observed with IV DARA in intermediate- or high-risk SMM pts during the phase 2 CENTAURUS study, we hypothesized that DARA SC may delay progression to MM versus active monitoring in pts with high-risk SMM. Methods: AQUILA is an ongoing, randomized, open-label, multicenter phase 3 study of DARA SC versus active monitoring in pts with high-risk SMM. D
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
The congophilic properties of organized fibrillary deposits should not be solely relied on in differentiating fibrillary GN from renal amyloidosis. Mass spectrometry and DNAJB9 immunohistochemistry can be useful in making this distinction.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
@rajshekharucms @Drjhoffmanmiami @rubinstein_md @AaronGoodman33 @MorieGertz And now learning that not all things that are Congo red positive are amyloid: fibrillary GN is an example of that https://t.co/e8mnwhyXzF
-
-
Mashup Score: 0
Amgen.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
@RahulBanerjeeMD @MGHCancerCenter @NoopurRajeMD @LeukemiaLymph @Eddie_Cliff Moreover, denosumab less likely than zoledronic acid to worsen renal function, especially in patients with underlying kidney dysfunction. Table from randomized study https://t.co/ITuY5m1W7V https://t.co/cusoNTy3SG
-
-
Mashup Score: 1Sequencing of nontransplant treatments in multiple myeloma patients with active disease - 3 year(s) ago
Abstract. The approval of several different classes of drugs in recent years has resulted in a dramatic expansion of treatment options for multiple myeloma pati
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
@End_myeloma @MAWJNJ @Mohty_EBMT @COMyCongress @TheIACH @szusmani @NoopurRajeMD Thanks @End_myeloma! I thought that table looked very familiar! Here is the link to the chapter that we @NoopurRajeMD wrote: https://t.co/xAxUl5SZVW
-
-
Mashup Score: 0Abstracts & Posters | ASCO Annual Meeting - 3 year(s) ago
Your PrivacyASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with…
Source: conferences.asco.orgCategories: Latest Headlines, Oncologists1Tweet-
@DavidSteensma @ASCO One approach (which may be easier and faster): just download the PDF of the abstracts: https://t.co/ixEQUZZpVI. This is one of the best features of ASCO that I wish other meetings adopted.
-
-
Mashup Score: 4SUMMARY - OncLive/Institutional Perspectives in Cancer/Multiple Myeloma/May 11, 2022/ET - 3 year(s) ago
OncLive® Institutional Perspectives in Cancer: Disease State, Month Day, Year. Oncology Webinar features research and clinical advances in oncology.
Source: event.onclive.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Join us (@NoopurRajeMD @betsyodonnellmd and Andrew Branagan from @MGHCancerCenter) virtually Wed May 11, 6:30-8 p.m. for discussions on relapsed multiple myeloma and the future of treatment. Register https://t.co/GnntoWUeuP @OncLive #mmsm https://t.co/wPnskpATHj
-
-
Mashup Score: 0
Background Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exhibited tolerability in patients with relapsed or refractory MM (RRMM). Methods This subgroup analysis evaluated D-Vd versus Vd in CASTOR based on cytogenetic…
Source: BioMed CentralCategories: Hem/Oncs, Latest HeadlinesTweet-
@HenrychihangFu1 @MorieGertz @CyclingDoctor One consideration in the standard risk subset analysis of CASTOR https://t.co/rg6DAWbSPH is that prior lenalidomide exposure was only 42%.
-
-
Mashup Score: 1Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome - PubMed - 3 year(s) ago
In historical attempts to treat morning sickness, use of the drug thalidomide led to the birth of thousands of children with severe birth defects. Despite their teratogenicity, thalidomide and related IMiD drugs are now a mainstay of cancer treatment; however, the molecular basis underlying the plei …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
@RahulBanerjeeMD @QuinlanSievers @UCSFIMChiefs @UCSFHospitals The connection between thalidomide and degradation of SALL4 in humans but not rats adds more to the teratogenicity story. https://t.co/wvIIMpUa8F
-
-
Mashup Score: 063rd ASH Annual Meeting and Exposition - 3 year(s) ago
63rd ASH Annual Meeting and Exposition
Categories: Hem/Oncs, Latest HeadlinesTweet-
@dgermain21 @ASH_hematology Try https://t.co/3jmwFZa8S4 (which was the link that was used during the meeting). It still works (not sure for how much longer); no description of it on the ASH website.
-
@VincentRK This is the dara v. observation study in SMM that was mentioned by @VincentRK https://t.co/upyjCBCxP9